Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on January 17, 2006
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi213
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/1/50    most recent
hyi213v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cho, K.-H.
Right arrow Articles by Kim, B.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cho, K.-H.
Right arrow Articles by Kim, B.-S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 Foundation for Promotion of Cancer Research
Received April 17, 2005
Accepted November 17, 2005

Clinical Trial Note

A Phase II Study of Single-Agent Gemcitabine as a Second-Line Treatment in Advanced Non-Small Cell Lung Cancer

Keun-Hyok Cho 1, Young-Bong Song 1, Ik-Sung Choi 1, Eun-Hee Cho 1, Jae-Won Choi 1, Young Mi Ahn 1, Yong Ho Roh 1, Seung-Hyun Nam 1, and Bong-Seog Kim 1 *

1 Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea

* To whom correspondence should be addressed.
Bong-Seog Kim, E-mail: seog{at}e-bohun.or.kr


  Abstract

Objective: To evaluate the efficacy and safety of the single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC) as second-line chemotherapy.

Methods: Between February 2002 and November 2004, a total of 27 patients, who had previously been treated with paclitaxel and platinum as first line chemotherapy, were enrolled in the study. Patients were treated with gemcitabine (1000 mg/m2) on days 1, 8 and 15 in a 28 day cycle. The response was assessed every two cycles. Toxicities were evaluated according to common toxicity criteria (CTC).

Results: The median age was 62 (range, 46-79) years old. Among the 27 patients, 26 were male. Twenty-three patients had an ECOG performance status of 0 or 1 and four patients had a status of 2. Pathologically, 24 patients had squamous cell carcinoma and 3 had adenocarcinoma. Partial responses were observed in 15 patients. All patients were evaluated for response and toxicity. The overall response rate was 18.5% (95% confidence interval, 5-33%) and the median response duration was 17 (range, 7.4 to 49+) weeks. The median time to progression was 10 (range, 7 to 34+) weeks. The median overall survival for all patients was 38 (range, 10 to 122+) weeks. During a total of 87 cycles, granulocytopenia greater than CTC grade 2 occurred in 7%, thrombocytopenia in 1% and anemia in 24% of case. Non-hematologic toxicities were minor and easily controlled. Conclusion: This study confirms the activity and safety of the single-agent gemcitabine as a second-line therapy in pretreated patients with advanced NSCLC.

Keywords: Gemcitabine; Second-line treatment; Non-small cell lung cancer.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.